Home›Neurology› Rosuvastatin May Improve Lipid and Inflammatory Markers Over Atorvastatin After Stroke or TIA
Rosuvastatin May Improve Lipid and Inflammatory Markers Over Atorvastatin After Stroke or TIARosuvastatin shows potential benefits for patients after a stroke
Medicina clinicaPublished October 5, 2026Study authors: Cueva-Cañola Luis E, Beltran-De la Fuente Andrea C, Ramírez Navarro Diana I, Carrión-Cuéllar Astrid …PubMed ↗DOI ↗Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret rosuvastatin's marker benefits cautiously; superiority over atorvastatin is not established.
This meta-analysis synthesized evidence comparing rosuvastatin with atorvastatin in patients after acute ischemic stroke or transient ischemic attack. The scope covered lipid and inflammatory markers, recurrent stroke, all-cause mortality, hemorrhagic stroke, and composite cardiovascular outcomes. Follow-up duration, sample size, and setting were not reported.
For lipid and inflammatory markers, rosuvastatin was associated with greater improvements than atorvastatin. Composite cardiovascular outcomes were more favorable with rosuvastatin, and hemorrhagic stroke rates were lower with rosuvastatin. However, recurrent stroke and all-cause mortality were similar between the two statins. Effect sizes, absolute numbers, and p-values or confidence intervals were not reported for any outcome.
Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. The authors note that the evidence is insufficient to establish clinical superiority of either statin. Funding and conflicts of interest were not reported.
The findings are associative and should be interpreted cautiously. The lack of effect estimates and safety data limits the strength of any practice conclusions. Clinicians should recognize that the available evidence does not support changing statin selection based on these results alone.
How this fits prior evidence
This meta-analysis extends prior coverage of statin effects after acute coronary syndrome, where high-intensity statin adherence correlated with greater LDL-C reductions and improved plaque stability post-AMI. It also contrasts with prior stroke and TIA coverage focused on antiplatelet strategies, such as dual antiplatelet therapy reducing major ischemic events in week 1 but increasing bleeding risk, and clopidogrel plus aspirin for 21 days providing favorable net clinical benefit. The current analysis addresses a gap by comparing two high-intensity statins specifically after ischemic stroke or TIA, but its associative findings and absent effect sizes limit direct comparison with those prior results.
Living with the aftermath of a stroke or a transient ischemic attack (a temporary blockage of blood flow) means managing long-term risks. Doctors often use statins to manage cholesterol and protect the heart, but not all statins are the same. This analysis looked at how two common options, rosuvastatin and atorvastatin, compare for patients who have already experienced a stroke.
The data shows that rosuvastatin led to greater improvements in lipid and inflammatory markers compared to atorvastatin. Additionally, patients taking rosuvastatin had lower rates of hemorrhagic stroke (bleeding in the brain) and more favorable composite cardiovascular outcomes. However, the results were very similar between the two drugs when it came to all-cause mortality and the risk of a recurrent stroke.
While these findings show some advantages for rosuvastatin in specific areas, the evidence is still not enough to say one is clearly better than the other for everyone. Because the data is limited, it is hard to declare a clear winner for clinical use. Talk to your doctor to decide which medication fits your specific health needs.
What this means for you:
Rosuvastatin shows better lipid markers and lower bleeding stroke rates, but evidence is not yet enough to prove superiority.
Common questions
How does rosuvastatin compare to atorvastatin after a stroke?
Rosuvastatin showed greater improvements in lipid and inflammatory markers compared to atorvastatin. It also showed lower rates of hemorrhagic stroke and more favorable composite cardiovascular outcomes. However, both drugs showed similar results regarding all-cause mortality and the risk of a recurrent stroke.
Is rosuvastatin safer than atorvastatin for stroke patients?
The study found that rosuvastatin was associated with lower rates of hemorrhagic stroke, which is a type of stroke caused by bleeding. However, the evidence is currently insufficient to establish that one statin is clinically superior to the other overall.
Does rosuvastatin reduce the risk of a second stroke?
The data showed that the risk of a recurrent stroke was similar between rosuvastatin and atorvastatin. Because the evidence is still limited, you should speak with your doctor to determine the best treatment plan for your specific situation.
BACKGROUND AND OBJECTIVE: Acute ischemic stroke (AIS) and transient ischemic attack (TIA) are leading causes of mortality and disability. High-intensity statins are central to secondary prevention, with guidelines recommending atorvastatin or rosuvastatin; however, comparative evidence post-stroke is limited. This study systematically reviewed literature comparing both agents after AIS/TIA.
MATERIAL AND METHODS: The protocol was registered in PROSPERO (CRD420261287374). PubMed, Embase, and Ovid MEDLINE were searched from inception to January 17, 2026, using predefined terms for statins and AIS/TIA.
RESULTS: Five studies were included (one randomized trial and four cohort studies). Compared with atorvastatin, rosuvastatin was associated with greater improvements in lipid and inflammatory markers. Despite these differences, rates of recurrent stroke and all-cause mortality were similar between treatments. However, rosuvastatin was associated with lower rates of hemorrhagic stroke and more favorable composite cardiovascular outcomes.
CONCLUSIONS: Evidence suggests biological differences but is insufficient to establish clinical superiority of either statin.
